Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | CASP1 | P29466 | 2/20 | 0.59 |
| ▸ | CASP7 | P55210 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7748018 | 0.98 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| Hydrochloric Acid SCHEMBL28692703 | 0.96 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| Trifluoroacetic Acid SCHEMBL3273637 | 0.82 | L3MBTL1 (0.53) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| SCHEMBL10368122 | 0.82 | CASP6 (0.62) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| SCHEMBL20480312 | 0.82 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| SCHEMBL246244 | 0.82 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| SCHEMBL19988546 | 0.82 | CASP6 (0.58) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| SCHEMBL22324148 | 0.82 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| SCHEMBL5521831 | 0.82 | CASP6 (0.62) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| SCHEMBL8123144 | 0.82 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2ACASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020206381-A1 | CEPHEM COMPOUNDS WITH LATENT REACTIVE GROUPS AND METHODS OF USING AND MAKING SAME | SUTTON LARRY D (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2019070973-A1 | CEPHEM COMPOUNDS WITH LATENT REACTIVE GROUPS | GLADIUS PHARMACEUTICALS CORPORATION (CA) | 2019-04-11 | — | — | WO | disclosed |
| US-20190100534-A1 | Cephem Compounds with Latent Reactive Groups | GLADIUS PHARMACEUTICALS INC (CA) | 2019-04-04 | — | — | US | disclosed |
| WO-2010097091-A1 | METHODS OF ADMINISTERING (4AR, 1OAR)-I-N-PROPYL-I, 2,3,4A7 S1IO7 IOA-OCTAHYDROBENZO [G] QUINOLINE-6,7-DIOL AND RELATED COMPOUNDS ACROSS THE ORAL MUCOSA, THE NASAL MUCOSA OR THE SKIN AND PHARMACEUTICAL COMPOSITIONS THEREOF | H. LUNDBECK A/S (DK) | 2010-09-02 | — | — | WO | disclosed |
| EP-2197883-A1 | CATECHOLAMINE DERIVATIVES USEFUL FOR THE TREATMENT OF PARKINSON' S DISEASE | H. Lundbeck A/S (DK) | 2010-06-23 | — | — | EP | disclosed |
| EP-2195291-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. Lundbeck A/S (DK) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009026934-A1 | CATECHOLAMINE DERIVATIVES USEFUL FOR THE TREATMENT OF PARKINSON' S DISEASE | H. LUNDBECK A/S (DK) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009026935-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. LUNDBECK A/S (DK) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100534-A1 | Cephem Compounds with Latent Reactive Groups | PGLS, GNE, COMT | ADRA1A 3377/4885ALDH1A1 1680/4885MEN1 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.